Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in Pediatric Patients

Abstract

Background: The emergence of infections due to multidrug-resistant Gram-negative bacilli (MDR-GNB) has led to the resurrection of colistin use. The data on colistin use and drug-related adverse effects in children are scarce. Aims: In this study, we aimed to evaluate the clinical efficacy and safety of colistin use in critically ill pediatric patients. Study Design: This study has a retrospective study design. Methods: Sixty-one critically ill children were identified through the department’s patient files archive during the period from January 2011 to November 2014. Results: Twenty-nine females and thirty-two males with a mean±standard deviation (SD) age of 61±9 months (range 0-216, median 12 months) received IV colistin due to MDR-GNB infections. Bacteremia (n=23, 37.7%) was the leading diagnosis, followed by pneumonia (n=19, 31%), clinical sepsis (n=7, 11.4%), wound infection (n=6, 9.8%), urinary tract infection (n=5, 8.1%) and meningitis (n=1, 1.6%). All of the isolates were resistant to carbapenems; however, all were susceptible to colistin. The isolated microorganisms in decreasing order of frequency were: Acinetobacter baumanni (n=27, 44.2%), Pseudomonas aeruginosa (n=17, 27.8%), Klebsiella pneumoniae (n=6, 9.8%), K. pneumoniae and Stenotrophomonas maltophilia (n=1, 1.6%), K. pneumoniae and A. baumanni (n=1, 1.6%), K. oxytoca (n=1, 1.6%) and Enterobacter cloacae (n=1, 1.6%). In seven patients, no microorganisms were detected; however, five of these patients were colonized by carbapenem-resistant K. pneumoniae. The mean duration of colistin therapy was 12 days (range 3-45). Colistin was administered concomitantly with one of the following antibiotics: carbapenem (n=50, %82), ampicillin-sulbactam (n=5, 8%), quinolones (n=5, 8%), rifampicin (n=1, 1.6%). Carbapenem was the most frequently used antibiotic. Nephrotoxicity was observed in only 1 patient, and we did not observe neurotoxicity in this study. All the patients received intravenous colistin (colisthimethate)  at a dosage of 5 mg/kg daily by dividing it in three equal doses. Seven (11.4%) patients died during the study period. Conclusion: Colistin appears to be a safe and efficacious drug for treating MDR-GNB infections in children.

Keywords

• Colistin, multidrug-resistant gram-negative infections, children

Kaynakça

1. 1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria:an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. [CrossRef]
2. 2. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:1079-81. [CrossRef]
3. 3. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected Gram-negative sepsis. JAMA 1995;274:338-45. [CrossRef]
4. 4. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 2011;6:653- 66. [CrossRef]
5. 5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41. [CrossRef]
6. 6. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14. [CrossRef]
7. 7. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012;18:18-29. [CrossRef]
8. 8. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40. Erratum in: Am J Infect Control 1988;16: 177. [CrossRef]

9. 9. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2. [CrossRef]
10. 10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrugresistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601. [CrossRef]
11. 11. X-Gen Pharmaceuticals Inc. Colistimethate for injection, USP: for intramuscular and intravenous use. [Accessed April 9, 2010]; Available from: http://x-gen.us/wp-content/uploads/2014/03/ Colistimethate_pi.pdf
12. 12. European Medicines Agency completes review of polymyxinbased medicines. (Published in 24/10/2014); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Press_release/2014/10/WC500176334.pdf
13. 13. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (Colistin) use in critically Ill children without cystic fibrosis. Pediatr Infect Dis J 2009;28:123-7. [CrossRef]
14. 14. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297-300. [CrossRef]
15. 15. Karbuz A, Özdemir H, Yaman A, Kocabaş BA, Ödek C, Güriz H, et al. The use of colistin in critically Ill children in a pediatric intensive care unit. Pediatr Infect Dis J 2014;33:19-24. [CrossRef]
16. 16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21. Wayne, PA, USA: CLSI; 2011.
17. 17. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical MIC breakpoints. Available from: http://www.eucast.org/clinical_breakpoints.
18. 18. Furtado GH, d’Azevedo PA, Santos AF, Gales AC, Pignatari AC, Medeiros EA. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007;30:315-9. [CrossRef]
19. 19. Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009;33:503. [CrossRef]
20. 20. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62. [CrossRef]
21. 21. Nation RL, Li J. Polymyxins. In: The Use of Antibiotics, Kucers A. editor. London: Heinemann; 2010:955. [CrossRef]
22. 22. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6. [CrossRef